HOME >> BIOLOGY >> NEWS
Experimental Biology 2007: Today's Research, Tomorrow's Health, April 28-May 2

d novel therapies based on molecules of the innate immune system.

The American Society for Pharmacology and Experimental Therapeutics offers symposia on cannabinoids (a chemical compound in cannabis or marijuana), endocannabinoids (a marijuana-like substance) and pain associated with inflammation, stress, psychiatric disorders, neurodegenerative disorders, and other disorders; the future of pharmacogenomics and its clinical applications; nanotechnology in disease therapeutics; osteoporosis and bone research (a symposium subtitled "no time to be bad to the bone"); toxicology of nanomaterials (including effects on the skin and lungs); the ways in which nicotine modulates adolescent brain plasticity, interacts with other drugs during sensitive developmental periods, and, when used along with alcohol by a woman during pregnancy, alters drug responsiveness in offspring; an examination of why children, adolescents and adults respond differently to antidepressants; studies of how perinatal stress, such as maternal separation, affects drug response and propensity to abuse drugs as an adult; and cardiovascular gene therapy.

The American Physiological Society program includes 16 societal or distinguished lectures and a Physiology Infocus session that focuses on novel technologies in physiology and medicine, such as advances in forensic medicine, new approaches in imaging, and the use of experimental evolution (selecting for particular physiological attributes in large laboratory populations) as a tool of physiological analysis. Other workshops include human subject research ethics and the challenge of presenting basic research in an anti-science, anti-evolution and anti-education era. Among topics for symposia or individual research presentations are: cancer and hypoxia (starving tumors of oxygen) ; pharmacogenomics of estrogen and cardiovascular disease; roles of intestinal epithelia and bacteria in inflammatory disease; and the potential benefits of
'"/>

Contact: Sylvia Wrobel
ebpress@bellsouth.net
770-270-0989
Federation of American Societies for Experimental Biology
25-Feb-2007


Page: 1 2 3 4 5

Related biology news :

1. 38 minority scientists receive travel fellowships to Experimental Biology 2007 in D.C.
2. Experimental Biology 2007 meets in Washington, D.C., April 28-May 2
3. Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy
4. Experimental RNA-based drug kills prostate cancer cells effectively and safely
5. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
6. Undergrads compete for American Physiological Society Bruce awards at Experimental Biology
7. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
8. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
9. Experimental evolution of yeast in the lab may illuminate early events in speciation
10. Advancing the biomedical frontier: Experimental Biology 2006
11. Experimental Biology 2006 meets in San Francisco April 1-5

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Experimental Biology Today Research Tomorrow Health April May

(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
(Date:7/29/2015)... 2015 Research and ... of the "Global Biosimilars Market, 2015 - ... The Global Biosimilars Market, 2015 - 2025, report ... biosimilars market. With the blockbuster biologics losing patent ... biosimilars are being viewed as viable substitutes to ...
(Date:7/29/2015)... July 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... will be released on Thursday, August 13, 2015, before ... Pfenex management will host a conference call to discuss ... press release outlining the financial results and business update ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and ...
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
Cached News: